We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.91B
1-Year Est. Return 304.52%
This Fund
S&P 500
This Quarter Est. Return
+11.75%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.92%
10 Year Est. Return
+28,184.58%
AUM
$1.02B
AUM Growth
+$38.1M
Cap. Flow
+$21.5M
Cap. Flow %
2.1%
Top 10 Hldgs %
51.66%
Holding
52
New
9
Increased
9
Reduced
24
Closed
1

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$28.1M
2
MRUS
Merus
MRUS
+$27.9M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$25.3M
4
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$19.7M
5
EOCN
Eocene Ltd. Ordinary Shares
EOCN
+$14.2M

Top Sells

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$87.2M
2
ARQL
Arqule Inc
ARQL
+$34.3M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$19.6M
4
ARRY
Array Biopharma Inc
ARRY
+$6.21M
5
RCUS icon
Arcus Biosciences
RCUS
+$4.86M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCUS icon
26
Arcus Biosciences
RCUS
$3.21B
$11.7M 1.15%
959,840
-309,948
-24% -$4.86M
IRWD icon
27
Ironwood Pharmaceuticals
IRWD
$681M
$11.6M 1.13%
724,418
-5,893,208
-89% -$87.2M
CDTX
28
DELISTED
Cidara Therapeutics
CDTX
$10M 0.98%
+96,534
New +$9.11M
PTGX icon
29
Protagonist Therapeutics
PTGX
$9.24B
$9.53M 0.93%
1,417,967
+1,012,367
+250% +$7.77M
OMED
30
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$9.47M 0.92%
4,099,589
-153,600
-4% -$447K
FSTX
31
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$9.31M 0.91%
196,488
-11,574
-6% -$642K
RGLS
32
DELISTED
Regulus Therapeutics
RGLS
$9.02M 0.88%
114,043
-2,409
-2% -$199K
SNDX icon
33
Syndax Pharmaceuticals
SNDX
$1.58B
$8.66M 0.85%
1,233,618
-2,000,000
-62% -$19.6M
VBIV
34
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$8.53M 0.83%
103,333
– –
ALBO
35
DELISTED
Albireo Pharma Inc
ALBO
$7.81M 0.76%
220,000
-5,000
-2% -$162K
CFRX
36
DELISTED
ContraFect Corporation
CFRX
$7.43M 0.73%
4,201
-174
-4% -$256K
PHXM
37
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$7.21M 0.7%
62,500
– –
XENE icon
38
Xenon Pharmaceuticals
XENE
$5.55B
$6.63M 0.65%
720,830
– –
ONCT
39
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$5.91M 0.58%
2,758
-1,597
-37% -$4.05M
SURF
40
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$5.45M 0.53%
+334,333
New +$4.84M
MACK
41
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$5.45M 0.53%
+1,411,557
New +$9.37M
ALPN
42
DELISTED
Alpine Immune Sciences Inc
ALPN
$4.87M 0.48%
643,059
-32,700
-5% -$269K
GNCA
43
DELISTED
Genocea Biosciences, Inc.
GNCA
$4.5M 0.44%
658,125
+33,125
+5% +$248K
FBRX
44
DELISTED
Forte Biosciences
FBRX
$4.4M 0.43%
1,256
-89
-7% -$326K
MTEM
45
DELISTED
Molecular Templates, Inc.
MTEM
$3.6M 0.35%
45,909
– –
VIRX
46
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.57M 0.35%
48,132
– –
EPIX
47
DELISTED
ESSA Pharma
EPIX
$2.09M 0.2%
552,791
+43,609
+9% +$163K
KDNY
48
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.07M 0.2%
59,193
-102,114
-63% -$3.92M
FRTX
49
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$1.53M 0.15%
4,230
-244
-5% -$115K
LOXO
50
DELISTED
Loxo Oncology, Inc
LOXO
$709K 0.07%
4,089
-297
-7% -$44.6K
1
2
3

Similar funds

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.91B AUM 14.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
AC
Anther Capital Hong Kong $3.91B AUM
FFGIM
Founders Fund Growth II Management San Francisco, California $3.9B AUM
AIM
ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

BVF Inc's Q2 2018 Portfolio in Review

As of Q2 2018, BVF Inc held 52 positions worth $1.02B, up 3.9% from $986M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

BVF Inc's Q2 2018 filing shows 9 new, 9 increased, 24 reduced and 1 closed positions. Its largest new stake was Mirati Therapeutics, Inc. Common Stock: 745,000 shares worth $36.7M. The largest sale was Ironwood Pharmaceuticals, an estimated $87.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • BVF Inc's largest Q2 2018 buy was Mirati Therapeutics, Inc. Common Stock: 745,000 shares worth $36.7M.
  • BVF Inc added most to Merus in Q2 2018, an estimated $27.9M increase.
  • BVF Inc's biggest Q2 2018 reduction was Ironwood Pharmaceuticals, cutting an estimated $87.2M.
  • BVF Inc fully exited Orexigen Therapeutics, Inc. in Q2 2018, selling an estimated $108K.
  • BVF Inc's ten largest holdings make up 52% of its $1.02B portfolio in Q2 2018.
  • BVF Inc opened 9 new positions and closed 1 in Q2 2018.
  • BVF Inc's portfolio value rose 3.9% quarter-over-quarter to $1.02B.

Based on BVF Inc's 13F filing for Q2 2018, filed 14 Aug 2018.